Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Nosopharm
Nosopharm
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Scleroderma treatment by Certa Therapeutics granted US FDA fast track
FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
Naobios and Sumagen sign exclusive partnership to develop HIV vaccine
Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
Rapid increase in purchasing teams expected at CPHI North America
Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Bio-Rad and Oncocyte partner to commercialise transplant monitoring with Droplet Digital PCR
The collaboration aims to provide researchers with tools to enable transformational monitoring of key biomarkers in solid tissue transplants
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
French collaboration aims to address antibiotic resistance
The project will involve the creation of chemical libraries of bioactive molecules for Nosopharm’s anti-infective screening campaigns against antibiotic resistance
Recruitment
Nosopharm bolsters supervisory board
Research & Development
Nosopharm joins European Gram-negative Antibacterial Engine (ENABLE) project to combat antibiotic resistance
The company aims to advance a promising antibacterial compound to clinical stage for the treatment of multidrug-resistant Gram-negative infections
Research & Development
Nosopharm secures funding of €870,000 to fight antibiotic resistance
Nosopharm has developed a new class of antibiotics and the funding will ensure their progression to preclinical development
Subscribe now